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Background: The small cell ovarian carcinoma of the hypercalcemic type (SCCOHT) which preferably affects young
women during regenerative age represents a rare and aggressive form of ovarian tumors with poor prognosis and
lacks an efficient therapy.
Methods and results: In vitro chemotherapy testing in a fluorescence assay using a recently developed cellular
model from a recurrent SCCOHT revealed sensitivity for certain epothilones, methotrexate and topotecan whereas
little if any cytotoxicity was observed with other chemotherapeutics including platin-based compounds. In particular,
epothilone B demonstrated a high sensitivity in contrast to ixabepilone with only little detectable effects. Western blot
and cell cycle analysis revealed that the epothilone B sensitivity was associated with increased Ser15 phosphorylation
of p53, a significant G1 and G2 cell cycle accumulation and subsequent cell death in subG1 phase. Moreover, tubulinβ3
expression in SMARCA4/BRG1-defective SCCOHT-1 in contrast to other ovarian cancer cells was also affected during
chemotherapy treatment. Increased extracellular Ca2+ levels further enhanced the epothilone B cytotoxicity in
SCCOHT-1 cells. These in vitro effects were also confirmed in vivo in NOD/scid mouse xenografts demonstrating an
attenuated tumor growth in epothilone B / Ca2+-treated mice. After 4d of subsequent treatment, the tumor sizes
were reduced by about 90% as compared to continuously growing control tumors. In parallel, a hypercalcemia in
control tumor-carrying mice was reverted to normal serum Ca2+ levels after epothilone B / Ca2+ therapy.
Conclusions: Taken together, these data demonstrated anti-tumorigenic effects of epothilone B / Ca2+ in SCCOHT
providing a focused therapeutic approach against this rare disease and arising recurrent tumors.
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Ovarian cancer represents one of the most lethal gyneco-
logic malignancy. A rare form of an aggressive ovarian
tumor is displayed by the small cell ovarian carcinoma of
the hypercalcemic type (SCCOHT). So far, no histogenetic
origin of SCCOHT has been identified and accordingly,
only little is known about tumor tissue characteristics of
SCCOHT. Initial immunohistochemical analysis of the
SCCOHT has postulated a germ cell-derived tumor [1] al-
though electron microscopy evaluations of tumor speci-
men reported SCCOHT as an epithelial-like originating
tumor [2]. Further analysis of SCCOHT tumor specimen* Correspondence: hass.ralf@mh-hannover.de
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unless otherwise stated.suggested an inhomogeneous tumor entity which neither
confirmed a germ cell-derived nor an epithelial cell-
derived tumor origin [3-5]. The heterogeneity of these
data may be explained in part by the limitations of biopsy
material from patients. An appropriate cellular model for
this tumor entity is represented by the BIN-67 cells [6].
Due to the unknown etiology, the SCCOHT which repre-
sents an aggressive form of ovarian tumors still remains
with poor prognosis and no efficient therapy. Thus, the
SCCOHT which is mostly accompanied by a paraendo-
crine hypercalcemia [2,7] preferably affects young women
between ages of 13 to 35 with lethal outcome in a short
period of time after diagnosis.
Potential therapeutic approaches to date are based
predominantly on certain histological SCCOHT tissue
examinations. The findings revealed that some areas of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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whereas the intermediate filament protein vimentin has
been described in the majority of cells [3]. In addition, cell
cycle analysis of several SCCOHT tumors by flow cytome-
try reported a broad distribution with 4.7% to 18% of S
phase cells and 1.5% to 19.5% of G2/M phase cells [8],
however, the histogenesis and further cell biological prop-
erties of the SCCOHT still remained poorly understood.
Recent studies of a variety of SCCOHT tissue samples re-
vealed a mutation in the SMARCA4 gene as a potential
marker for the SCCOHT [9-11].
Moreover, interaction of the tumor cells with adjacent
populations within the tumor microenvironment includ-
ing endothelial cells and mesenchymal stem cells support
tumor vascularization and growth, however, such inter-
action alters the functionality and induces differentiation
processes of the stem cells which can contribute to protect
the tumorigenic target cells [12,13]. Consequently, reason-
able approaches for the treatment of SCCOHT patients or
a sufficient (chemo)therapeutic management are difficult
and remain unclear. A recently developed cellular model
of SCCOHT-1 cells derived from a primary culture of bi-
opsy material after surgery of a 31-year-old patient with
recurrent SCCOHT confirmed a cell type with epithelial/
mesenchymal properties by partially expressing epithelial
cytokeratins as well as the mesenchymal-type intermediate
filament vimentin. Expression of surface markers in
SCCOHT-1 includes CD15, CD29, CD44 and CD90 [14].
Based upon this cellular model of SCCOHT-1 cells, we ex-
amined in the present study cytotoxic effects of a variety
of anti-tumor compounds in comparison to established
human ovarian adenocarcinoma cell lines including NIH:
OVCAR-3 and SK-OV-3 with known resistance to cis-
platin [15]. The obtained in vitro effects in SCCOHT-1
cells with a focus on microtubule-stabilizing chemothera-
peutics including epothilone B were investigated at the
protein level to identify certain molecular effects and
mechanisms. Moreover, epothilone B in combination with
calcium was applied in NOD/scid mouse tumor xeno-
grafts to verify the in vitro therapeutic effects also in vivo.
Our findings provide a more detailed understanding of
potential compounds to target ovarian cancer cells exhi-
biting resistance to a variety of chemotherapeutics.
Material and methods
Cell culture
Primary human SCCOHT-1 cells
SCCOHT-1 cells were derived as a spontaneously per-
manent growing primary culture from a tumor biopsy
after surgery of a 31-year-old patient with recurrent
SCCOHT [14]. Informed written consent was obtained
from the patient for the use of this material and the
study has been approved by the Ethics Committee of
Hannover Medical School, Project #3916 on June 15th,2005. The SCCOHT-1 cells were cultured in RPMI 1640
supplemented with 10% (v/v) fetal calf serum, 2mM L-
glutamine, 100U/ml penicillin and 100 μg/ml strepto-
mycin. The tissue culture was performed at 37°C in a
humidified atmosphere of 5% (v/v) CO2 and the medium
was changed at intervals of 3 to 4 days. For subculture,
the loosely attached cells were mechanically collected,
centrifuged (320 g/6 min), and resuspended in growth
medium at a cell viability of >95% as determined in a
hemocytometer using the trypan blue exclusion test.
The proliferation of SCCOHT-1 cells was measured in a
fluorescence-based microtiter plate assay following trans-
duction of SCCOHT-1 cells with a 3rd generation lenti-
viral SIN vector containing the eGFP gene as previously
described for these cells [14].
The human SCCOHT cell line BIN-67 (kindly provided
by Dr. Barbara Vanderhyden, University of Ottawa,
Canada) was cultured with DMEM/F12 : DMEM medium
(1:1) (Sigma Aldrich, St. Louis, MO) supplemented with
20% (v/v) fetal calf serum, 2mM L-glutamine, 100U/ml
penicillin and 100 μg/ml streptomycin.
Human alveolar adenocarcinoma A549 cell line (kindly
provided by Dr. Detlef Neumann, Hannover Medical School,
Germany) were cultured with DMEM (Sigma) supple-
mented with 10% (v/v) fetal calf serum, 2mM L-glutamine,
100U/ml penicillin and 100 μg/ml streptomycin.
Human ovarian adenocarcinoma cell lines
Human NIH:OVCAR-3 ovarian cancer cells (ATCC®
#HTB-161™) were commercially obtained in passage 76
(P76) from the Institute for Applied Cell Culture (IAZ),
Munich, Germany. The SK-OV-3 ovarian cancer cells
(ATCC® #HTB-77™) were commercially obtained in
P25 from the ATCC, Manassas, VA, USA. These ovarian
adenocarcinoma cell lines were originally established
from the malignant ascites of a patient with progressive
adenocarcinoma of the ovary, respectively. The cells
were cultivated at about 1,750 cells/cm2 in RPMI 1640
supplemented with 10% (v/v) fetal calf serum, 2mM
L-glutamine, 100U/ml penicillin and 100 μg/ml strepto-
mycin. Subculture was performed by trypsin/EDTA
(Biochrom GmbH, Berlin, Germany) treatment for 5 min
at 37°C. For the experiments NIH:OVCAR-3 cells were
used in P86 to P118 and SK-OV-3 cells were used in P37
to P39. For fluorescence measurement in an appropriate
proliferation assay the NIH:OVCAR-3 as well as the
SK-OV-3 cells have also been transduced with a 3rd gen-
eration lentiviral SIN vector containing the eGFP gene
similar to SCCOHT-1 cells.
Authentication of SCCOHT-1, NIH:OVCAR-3, and
SK-OV-3 cells was performed by short tandem repeat
(STR) fragment analysis using the GenomeLab human
STR primer set (Beckman Coulter Inc., Fullerton, CA,
USA). PCR products were sequenced in a CEQ8000
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GenomeLab DNA size standard kit-600 (Beckman
Coulter). The results of SCCOHT-1 were similar to the
original SCCOHT patient cells cultured in our lab and
the NIH:OVCAR-3 and SK-OV-3 cell lines results were
similar to the STR database provided by the Deutsche
Sammlung von Mikroorganismen und Zellkulturen (DSMZ,
Braunschweig, Germany).
Proliferation measurement by fluoroscan assay
The ovarian cancer cells were incubated with different
concentrations for each of the chemotherapeutic com-
pounds. The compounds and their concentrations used
in the cell culture are:
carboplatin (320 μM; Carbomedac, Medac GmbH, Hamburg,
Germany), cisplatin (320 μM; Bristol-Myers-Squibb),
cyclophosphamide (1.28 mM; Cyclophostin, Pharmacia
GmbH, Erlangen, Germany), cytarabine (320 μM; Ara C,
Sigma Aldrich GmbH, München, Germany), 5’-fluorouracil
(320 μM; Gry-Pharma GmbH, Kirchzarten, Germany),
doxorubicin (1.28 μM; Sigma), methotrexate (320nM; Hexal
AG, Holzkirchen, Germany), topotecan (320nM; Glaxo
Smithkline GmbH&Co KG, Munich), taxol (160nM;
Paclitaxel, Bristol-Myers-Squibb GmbH&Co KGaA, Munich),
epothilone A (160nM; GBF Braunschweig, Germany),
epothilone B (40nM; GBF Braunschweig, Germany), and
ixabepilone (80 μM; Bristol-Myers-Squibb), respectively.
For fluorescence measurement the different eGFP-
transduced ovarian cancer populations were seeded at
3,000 cells/well with standard culture medium (100 μL/
well) in flat bottom 96-well plates (Nunc/ThermoFischer,
Roskilde, Denmark) and incubated overnight to allow at-
tachment. Thereafter, 100 μl of culture medium was
added to the cells as control and in further wells 100 μl
of culture medium with the maximal solvent concentra-
tion was added to the cells as solvent control, respectively.
Moreover, 100 μl of the chemotherapeutic compounds
were added to the cells and dosed in a 2-fold serial dilu-
tion. Each plate was applied with a cells-only control in
culture medium and a maximal solvent concentration
control, respectively (Table 1). The cell viability obtained
with the appropriate chemotherapeutic compounds was
then normalized to these controls on a plate by plate basis
and a drug-dose–response analysis was performed for
the different compounds in the 3 different ovarian can-
cer cell populations. Following incubation of the cells
for 72 h, the medium was removed and the cells were
lysed with 5% (w/v) SDS. Afterwards, the fluorescence
intensities of GFP in the cell homogenate which corre-
sponded to the appropriate cell number of ovarian can-
cer cells was measured at excitation 485 nm/emission
520 nm using the Fluoroscan Ascent Fl (Thermo Fisher
Scientific). The resulting fluorescent signal was first
normalized to the mean signal of the cells only wells tocontrol for seeding variability and then to the mean sig-
nal of the solvent-only control.
Cell cycle analysis
The cell cycle analysis was performed as described previ-
ously [16]. Briefly, 9.3 × 103 cells/cm2 were seeded in
culture plates (diameter 10 cm; Greiner Bio-one GmbH,
Frickenhausen, Germany) overnight to allow attachment
of the cells and adjustment to the culture conditions.
Following incubation with 1 μM cisplatin, or 1 μM car-
boplatin, or 2nM epothilone B for 48 h, the cells were
fixed in 70% (v/v) ice-cold ethanol at 4°C for 24 h.
Thereafter, about 5 × 105 fixed cells were stained with
CyStain DNA 2 step kit (Partec GmbH, Münster, Germany)
and filtered through a 50 μm filter. The samples were then
analyzed in a Galaxy flow cytometer (Partec) using the
MultiCycle cell cycle software (Phoenix Flow Systems Inc.,
San Diego, CA).
Immunoblot analysis
For immunoblot analysis, untreated and chemotherapeu-
tic agents-stimulated SCCOHT-1GFP, NIH:OVCAR-3GFP
and SK-OV-3GFP cells were washed three times in ice-
cold PBS and lysed in a reswelling buffer containing 8 M
urea (Carl Roth GmbH Co KG, Karlsruhe, Germany),
1% CHAPS (3-[(3-Cholamidopropyl)dimethylammonio]-
1-propanesulfonate) (Carl Roth GmbH Co KG), 0.5% (v/v)
Pharmalyte 3 –10 (GE Healthcare Europe GmbH, Freiburg,
Germany), 0.002% (w/v) bromophenol blue (SERVA
Electrophoresis GmbH, Heidelberg, Germany) and freshly
prepared 0.4% (w/v) DTT (Dithiothreitol) (Carl Roth
GmbH Co KG). Protein concentration was adjusted using
the colorimetric BCA-assay (ThermoScientic, Rockford,
IL, USA), subjected to SDS-polyacrylamide gel electro-
phoresis and transferred to a hybond-C extra nitrocellu-
lose membrane (GE Healthcare). The membranes were
blocked with PBS containing 5% FCS and 0.05% Tween-
20 (PBS/Tween). After washing four times with PBS/
Tween, the membranes were incubated with the pri-
mary antibodies (monoclonal anti-BRG-1 (dilution 1:1,000;
ab110641; Abcam plc, Cambridge, UK); polyclonal
anti-p53[pSer15] (dilution 1:1,000; Cell Signaling Technology,
Beverly, MA, USA); polyclonal anti-p53 (dilution
1:1,000; Cell Signaling Technology); monoclonal anti-
HSP27[pSer82] (dilution 1:200; clone 5B9, Enzo GmbH,
Lörrach, Germany); monoclonal anti-tubulinβ3 (dilution
1:500; clone TU-20, Novus Biologicals Ltd., Cambridge,
UK); monoclonal anti-β-actin (dilution 1:5,000; clone
AC-15; Sigma-Aldrich) and monoclonal anti-GAPDH
(dilution 1:200; clone AC-15 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA)) overnight at 4°C. Thereafter, the
membranes were washed four times with PBS/Tween
and incubated with the appropriate horseradish peroxidase-
conjugated anti-mouse IgG (dilution 1:5,000) or anti-rabbit









Cytarabine 1.6 × 100 H2O 160 μM 8.1 × 10
-6 1.0 × 10-6 1.1 × 10-7
Cisplatin 2.0 × 10–2 NaCl 160 μM 2.3 × 10-5 3.3 × 10-6 1.7 × 10-6
Carboplatin 5.0 × 10–3 NaCl 160 μM 7.9 × 10-5 8.8 × 10-6 7.0 × 10-6
Cyclophosphamide 7.5 × 10–3 NaCl 640 μM 1.0 × 10-5 2.3 × 10-4 1.0 × 10-4
Methotrexate 3.0 × 10–5 NaCl/ 2.0 × 10–1 PBS 160 nM 4.7 × 10-9 5.7 × 10-9 5.9 × 10-9
Topotecan 7.0 × 10–3 H2O/ 2.0 × 10
–1 PBS 160 nM 3.6 × 10-9 1.8 × 10-8 5.0 × 10-9
Doxorubicin 3.0 × 10–2 H2O/ 2.0 × 10
–1 PBS 640 nM 2.0 × 10-8 1.3 × 10-7 2.9 × 10-8
5‘-fluorouracil 4.0 × 10–4 NaCl/ 2.0 × 10–1 PBS 160 μM 1.9 × 10-5 3.5 × 10-6 1.1 × 10-6
Epothilone A 8.0 × 10–3 DMSO/ 2.0 × 10–1 PBS 80 nM 3.3 × 10-9 2.9 × 10-9 2.2 × 10-9
Epothilone B 2.0 × 10–3 DMSO/ 2.0 × 10–1 PBS 20 nM 1.5 × 10-9 2.9 × 10-10 9.8 × 10-11
Taxol 6.0 × 10–4 ethanlol/ 2.0 × 10–1 PBS 80 nM 2.2 × 10-9 2.4 × 10-9 1.4 × 10-9
Ixabepilone 2.0 × 10–1 ethanol 40 μM 1.1 × 10-6 1.6 × 10-6 9.8 × 10-7
The maximal chemotherapeutic compound concentration indicates the highest initial concentration on the cells in the well followed by 2-fold serial dilutions.
The IC50 values of the appropriate chemotherapeutic compounds were calculated from the drug-dose–response curves after normalization to the mean signal of
the cells-only control and then to the mean signal of the solvent-only control.
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(all from GE Healthcare, Freiburg, Germany) for 1 h/room
temperature. The membranes were washed with PBS/
Tween and visualized by autoradiography using the
ECL-detection kit (GE Healthcare). Quantification of
the blots was performed by densitometry scanning using
the Image J program.
In vivo experiments
Animal research using NOD/scid mice was carried out
by following internationally recognized guidelines on
animal welfare and has been approved by the institu-
tional licensing committee ref. #33.14-42502-04-12/0814
on June 22nd, 2012.
About 1 x 106 GFP-labeled SCCOHT-1 cells previously
cultured in serum-free HybridoMed DIF 1000 medium
to avoid non-specific serum effects were injected sub-
cutaneously into 5 to 6 weeks old female NOD/scid
mice, respectively. After about 18 days post injection, all
mice with SCCOHT-1GFP cells had developed subcuta-
neous tumors. A therapeutic approach of the tumors
was first tested with a daily subcutaneous injection of
only 200 μl epithilone B (10 μM Epo B) at the tumor site
for 2 days. To test possible synergistic effects of calcium
and epothilone B in a further set of experiments, tumor-
carrying mice were divided into 3 treatment groups. The
first group represented the control tumor group with 5
animals and was injected subcutaneously with 200 μl of
0.9% NaCl at the tumor site every day. The second
group with 5 animals was injected subcutaneously with
200 μl Ca2+ (5 mM) in 0.9% NaCl at the tumor site every
day. The third group of 5 animals with tumor-carryingmice was injected subcutaneously with 200 μl Ca2+
(5 mM) together with 10 μM Epo B in 0.9% NaCl at the
tumor site every day. The tumor length (L) and width
(W) in each animal was measured on a daily basis and
the resulting tumor size was calculated as ½ L × W2
where L is the longer of the 2 measurements according
to the calculation of ellipsoid tumor forms [17]. The
treatment was started at an initial tumor size of approxi-
mately 2 to 3 mm3.
At the end of the experiments, the animals were sacri-
ficed by CO2 anesthesia and cervical dislocation. Follow-
ing UV light examination for the detection of GFP
positive tissue, the tumors were dissected whereby
tumor weight and the corresponding animal weight were
determined.
For calcium measurements cardial blood was taken from
the tumor-carrying NOD/scid mice after therapy and serum
was prepared and analyzed for Ca2+ concentration using the
Calcium Gen.2 reagent kit (Roche Diagnostics, Mannheim,
Germany). The Ca2+ test is based on a color reaction with
the chromophor 5-nitro-5’-methyl-1,2-bis(o-aminophenoxy)
ethane- N,N,N',N'-tetraacetic acid (NM-BAPTA) according
to the manufacturer’s instruction (Roche Diagnostics).
Results
To date, little if any successful chemotherapy is available
for the poor prognosis SCCOHT and therefore, in vitro
testing was performed using a recently developed cellular
model of human SCCOHT-1 cells derived from a recur-
rent small cell ovarian carcinoma of the hypercalcemic
type [14]. The proliferative capacity of SCCOHT-1 cells
was tested in comparison to NIH:OVCAR-3 and SK-OV-3
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GFP-labeled cells following treatment with different che-
motherapeutic compounds for 72 h (Figure 1A-C). DMSO
as an initial solvent for certain compounds was diluted to
less than 0.1% (v/v) in the final concentration whereby in-
cubation of the cells with even 0.2% (v/v) DMSO dis-
played no detectable effects as compared to control cells
without DMSO reaching a proliferation rate of 104.3% ±
9.2% (n = 6) after 72 h.
Incubation of the cells with cisplatin revealed an IC50
of 2.3 × 10−5 M in SCCOHT-1GFP cells and 3.3 × 10−6 M
and 1.7x10−6 M in SK-OV-3GFP and NIH:OVCAR-3GFP
cells, respectively (Figure 1A). Likewise, little effects on
the proliferation of these 3 ovarian cancer populations
were observed after exposure to carboplatin for up to 72 h
(Figure 1A, Table 1). Only a marginal growth inhib-
ition of SCCOHT-1GFP, SK-OV-3GFP and NIH:OVCAR-
3GFP cells was also detectable following incubation of the
cells with cytarabine and even less with cyclophosphamide
(Figure 1A, Table 1). Similarly, 5’-fluoruracil displayed
only little effects on the proliferation of the 3 ovarian can-
cer cell types (Figure 1B, Table 1). In contrast, exposure to
doxorubicin, topotecan and methotrexate was associatedFigure 1 Sensitivity of human ovarian cancer cells for chemotherapeu
SK-OV-3GFP cells were incubated with different concentrations of chemothe
capacity was measured by the fluoroscan assay. Analysis of a drug-dose–re
performed using GraphPad Prism-6. For calculation of the drug-dose–respo
culture medium and to the maximal solvent concentration control of the cwith a significantly elevated inhibiton of the proliferative
capacity in SCCOHT-1GFP, SK-OV-3GFP and NIH:
OVCAR-3GFP cells, respectively (Figure 1B, Table 1).
Mitotic inhibitors which stabilize the microtubules in-
cluding taxol and epothilones exhibited different anti-
proliferative effects. Thus, taxol revealed a growth reduc-
tion of in SCCOHT-1GFP with a IC50 of 2.2nM which was
enhanced in NIH:OVCAR-3 cells displaying an IC50 of
1.4nM but less pronounced in SK-OV-3GFP cells with an
IC50 of 2.4nM (Figure 1C, Table 1). Whereas epothilone
A demonstrated a slightly reduced sensitivity as compared
to taxol, treatment of the 3 different ovarian cancer cell
populations to epothilone B revealed the highest growth
inhibition tested in this study displaying an IC50 of 1.5nM
for SCCOHT-1GFP, 0.3nM for SK-OV-3GFP, and 0.098nM
for NIH:OVCAR-3GFP cells (Figure 1C, Table 1). In con-
trast, only a low responsiveness of the cells was observed
to ixabepilone with IC50 value in the micromolar range
(Figure 1C, Table 1).
Together, these findings demonstrated differences in the
chemotherapeutic sensitivity of these 3 ovarian cancer pop-
ulations. Moreover, topotecan, methotrexate, taxol and
epothilone B appeared as the most potent chemotherapeutictic compounds (A-C). SCCOHT-1GFP cells, NIH:OVCAR-3GFP and
rapeutic compounds for 72 h, respectively, and the proliferative
sponse to define IC50 concentrations for all compounds was
nse curves, the data were normalized to the cells-only control in
orresponding compound, respectively.
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potency for epothilone B.
Further analysis was performed to test the effects of
epothilone B on the cell cycle progression of the ovarian
cancer cells in comparison to cisplatin or carboplatin
which are frequently used in a combination with eto-
poside or taxol, respectively, for treatment of the
SCCOHT [18,19]. Flow cytometric cell cycle analysis of
logarithmically-growing SCCOHT-1GFP cells revealed a
distribution of continuously proliferating cells with
about 68% in G0/G1 phase, 9% in S phase and 23% in
the mitotic G2/M phase as evaluated by the MultiCycle
cell cycle software (Figure 2A). A similar cell cycle dis-
tribution of continuously proliferating cells was ob-
served following incubation of SCCOHT-1GFP cells with
either 1 μM cisplatin or 1 μM carboplatin for 48 h. In
contrast, treatment of SCCOHT-1GFP cells with a 500-
fold reduced concentration of 2 nM epothilone B for
48 h was associated with G0/G1 cell cycle arrest and a
significant accumulation of dead cells in the subG1
phase (Figure 2A). Likewise, the platin-resistent ovarian
cancer cell lines NIH:OVCAR-3 and SK-OV-3 demon-
strated a paralleled cell cycle pattern following exposure
to 1 μM cisplatin or 1 μM carboplatin or 2 nM epothi-
lone B for 48 h whereby SK-OV-3 also displayed an ac-
cumulation in G2/M upon epothilone B exposure
(Figure 2A). The SCCOHT-derived cell line BIN-67
demonstrated platin-compound resistance although
some subG1 accumulation was detectable following
treatment with 1 μM carboplatine for 48 h. Moreover,
incubation of BIN-67 cells to 2 nM epothilone B re-
vealed an accumulation in G2/M phase (Figure 2A).
These findings substantiated the unresponsiveness of
BIN-67 and SCCOHT-1 cells as well as NIH:OVCAR-3
and SK-OV-3 cells to platin-based compounds. More-
over, growth inhibitory effects of epothilone B associ-
ated with significant cellular damage and cell death
were confirmed in the ovarian cancer lines except for
BIN-67 cells with a markedly reduced sensitivity.
Differences between ovarian cancer cells and cells de-
rived from SCCOHT have been previously reported by a
mutation in the SMARCA4 gene as a potential marker for
the SCCOHT [9-11]. Western blot analysis of BRG-1 as
the protein product of the SMARCA4 gene revealed a pro-
nounced expression in the NIH:OVCAR-3 and SK-OV-3
ovarian cancer cells, however, little if any BRG-1 protein
was detectable in SCCOHT-1 cells (Figure 2B). Likewise,
BRG-1 was absent in human alveolar adenocarcinoma
A549 cells and in the BIN-67 cell line as previously re-
ported [11] (Figure 2B), suggesting also a SMARCA4
defect in SCCOHT-1 cells. Detection of β-actin expression
was used as a loading control (Figure 2B).
Whereas cellular and DNA damage activate a cascade of re-
pair mechanisms involving p53 and distinct phosphorylationprocesses of this tumor suppressor protein, the different
responses of SCCOHT-1 cells observed with taxol and
certain epothilones, particularly epothilone B and ixabepi-
lone, were evaluated by Western blot analysis. Thus, only
marginal differences were observed for the protein level of
p53 expression in SCCOHT-1 cells following treatment
with either taxol, epithilone A, epithilone B, or ixabepi-
lone. However, there was a significantly enhanced detec-
tion of phosphorylated p53 at serine15 (p53[pSer15])
particularly between 24 h to 48 h after epothilone B treat-
ment (Figure 3). Likewise, an elevated phosphorylation of
the heat shock protein HSP27 at serine 82 (HSP27[pSer82])
could be detected within 24 h to 48 h of epothilone B
exposure together with unchanged control expression of
GAPDH (Figure 3). Quantification by densitometry scan-
ning also revealed an elevated expression of p53[pSer15] in
taxol-stimulated SCCOHT-1 cells, however, these levels
remained significantly lower as compared to those ob-
served after epithilone B treatment.
A comparison of distinct chemotherapeutic effects be-
tween SCCOHT-1 and NIH:OVCAR-3 cells revealed lit-
tle if any change in p53 protein expression of the
investigated compounds, whereby densitometric analysis
revealed slightly induced p53 levels in the compound-
treated NIH:OVCAR-3 as compared to SCCOHT-1 cells
(Figure 4). A significant difference, however, was ob-
served for the tubulinβ3 protein level which was consti-
tutively expressed already in untreated SCCOHT-1 cells
and decreased after methotrexate treatment in contrast
to undetectable tubulinβ3 protein in NIH:OVCAR-3
cells (Figure 4). Conversely, HSP27[pSer82] was signifi-
cantly higher and unaltered expressed in NIH:OVCAR-3
cells as in SCCOHT-1 cells whereby incubation with
epothilone B for 24 h was associated with an increase of
HSP27[pSer82] protein levels in SCCOHT-1 cells (Figure 4).
SK-OV-3 cells are reported as p53 defective and a similar
expression pattern as compared to NIH:OVCAR-3 cells
was also observed for HSP27[pSer82] and undetectable
tubulinβ3 (data not shown).
To further address the question whether these in vitro
effects of epothilone B on SCCOHT-1 cells may also be
effective in vivo, subcutaneous tumors were induced in
NOD/scid mouse xenografts. Injection of 106 GFP-
labeled SCCOHT-1 cells resulted in a detectable tumor
development within 2–3 weeks. First, NOD/scid mouse
tumors were dissected and re-cultured to investigate
whether the cells obtained from the re-cultured tumors
maintain a similar chemotherapeutic sensitivity observed
during previous in vitro culture of SCCOHT-1GFP cells.
Indeed, incubation of the NOD/scid mouse tumors re-
cultured cells demonstrated a significantly increased sen-
sitivity for epothilone B after 48 h and 72 h, respectively,
whereas the responsiveness to topotecan-treated cells
remained unaltered (Figure 5A). Conversely, a higher
Figure 2 Cell cycle analysis of ovarian cancer cells after chemotherapeutic compound application (A) and SMARCA4/BRG-1 protein
expression in human ovarian cancer cells (B). Cell cycle analysis (A) was performed by flow cytometry in SCCOHT-1GFP, NIH:OVCAR-3GFP,
SK-OV-3GFP and BIN-67 cells after treatment with 1 μM cisplatin, or 1 μM carboplatin, or 2 nM epothilone B for 48 h, respectively. Western blot
analysis (B) of BRG-1 protein was performed in steady state of two ovarian carcinoma cell lines (NIH:OVCAR-3 and SK-OV-3) as compared to
SCCOHT-derived cells (SCCOHT-1 and BIN-67). The absence of BRG-1 in human alveolar adenocarcinoma A549 cells was used as a control and
expression of β-actin served as a loading control.
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Figure 3 Western blot analysis was performed in SCCOHT-1 cells, treated with 4 nM of either taxol, epothilone A (EpoA), epothilone B
(EpoB), or ixabepilone (Ixa) for 24 h, 48 h, and 72 h, respectively. Protein aliquots of the corresponding cell homogenates were analysed for
the expression of p53, phosphorylated p53 at serine-15, and phosphorylated heat shock protein (HSP27) at serine-82. The unaltered expression of
GAPDH served as a control for equal loading. Quantification of the blots by densitometry scanning was normalized against the appropriate
GAPDH expression and the relative expression levels were documented as bar diagram below the corresponding Western blots.
Figure 4 Comparison of protein expression in SCCOHT-1 and NIH:OVACAR-3 cells. Western blot analysis was performed in SCCOHT-1GFP
and NIH:OVCAR-3GFP, to compare the protein expression levels of p53, tubulinβ3, and phosphorylated heat shock protein (HSP27) at serine-82
after a 24 h incubation of the 2 cell types with 2 nM of ixabepilone (Ixa), epothilone B (EpoB), methotrexate (MTX), and 5’-fluorouracil (5FU),
respectively. The unaltered expression of GAPDH served as a control for equal loading, respectively. Quantification of the blots by densitometry
scanning was normalized against the appropriate GAPDH expression and the relative expression levels were documented as bar diagram below
the corresponding Western blots.
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Figure 5 Chemotherapeutic sensitivity of re-cultured SCCOHT-1GFP cells from xenograft tumors (A) and sensitivity of SCCOHT-1 cells to
Ca2+ and Epo B (B). SCCOHT-1GFP cells and re-cultured cells obtained from a SCCOHT-1GFP-induced tumor in NOD/scid mice (A) were incubated
with 2 nM epothilone B (EpoB), 20 nM topotecan (Topo), and 20 nM doxorubicin (Doxo) for 48 h and 72 h, respectively, and the proliferative
capacity was measured by the fluoroscan assay. Fluorescence data of the non-treated control cells were calculated as 100% of relative fluorescence
intensity. Data represent the mean ± s.d. (n = 10 for each control; n = 9 for each chemotherapeutic compounds). Statistical analysis between
the SCCOHT-1GFP cells and re-cultured NOD/scid tumor SCCOHT-1GFP cells after treatment with the chemotherapeutics was calculated by 2-way
ANOVA following Tukey’s multiple comparison test (ns = not significant; *= significant (p < 0.0001)). SCCOHT-1GFP cells were incubated with
either 1.6 mM CaCl2 (1.6 mM Ca
2+), 2 nM epothilone B (EpoB), or a combination of 2 nM EpoB + 1.6 mM Ca2+ in a fluoroscan assay for 24 h up
to 72 h (B), respectively. Fluorescence data of the non-treated control cells were calculated as 100% of relative fluorescence intensity. Data
represent the mean ± s.d. (n = 10). Statistical analysis was conducted between SCCOHT-1GFP cells in control medium and after exposure to 1.6 mM
Ca2+ as well as between SCCOHT-1GFP cells in the presence of 2 nM Epo B and SCCOHT-1GFP cells after exposure to 2 nM EpoB + 1.6 mM Ca2+ by
unpaired Student's t-test (*P < 0.0001; **P < 0.00001).
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significant after 72 h as statistically analyzed by 2-way
ANOVA (Figure 5A). According to the hypercalcemiawhich accompanies this tumor disease, additional ques-
tions were addressed whether exogenous calcium affects
SCCOHT-1 tumor cell growth in vitro together with
Figure 6 In vivo effects of different therapeutic approaches were examined in NOD/scid mice by evaluation of the tumor size each
day in the course of the therapy and by calculation of the relation of tumor weight/mouse weight after tumor dissection at the end of
the experiment. Subcutaneous tumors were induced in NOD/scid mice within 18d following injection of about 106 SCCOHT-1GFP cells. Thereafter,
different therapeutic approaches were applied by injection of 200 μl of either 0.9% NaCl, or 5 mM CaCl2, or 10 μM epothilone B (EpoB), or 5 mM
CaCl2 + 10 μM EpoB each day. A. The relation of tumor weight / mouse weight was calculated after 2d of subsequent injections for control tumors
(NaCl) (n = 2) and EpoB-treated tumors (n = 2). B. The relation of tumor weight / mouse weight was calculated after 4d of subsequent injections as the
mean ± s.d. for control tumors (NaCl) (n = 5), Ca2+-treated tumors (n = 5), and Ca2+ + EpoB-treated tumors (n = 4). Statistical analysis was conducted by
1-way ANOVA test (*p = 0.027). C. The tumor size was evaluated each day at 4 consecutive days of subsequent injections as the mean ± s.d. for control
tumors (NaCl) (n = 5), Ca2+-treated tumors (n = 5), and Ca2+ + EpoB-treated tumors (n = 4). Statistical analysis was calculated by unpaired Student's t-test
between Ca2+-treated tumors and the NaCl-treated tumor sizes as well as between Ca2+ + EpoB-treated tumors and the NaCl-treated tumor sizes at the
corresponding time points, respectively (*P < 0.05; **P < 0.01).
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ciated with a continuously reduced proliferation of
SCCOHT-1 cells in the fluoroscan assay by about 22.4% ±
4.6% (n = 10) after 72 h (Figure 5B). However, Ca2+ exhib-
ited at least additive effects together with epothilone B
and further diminished the epothilone B-mediatedprogressive growth reduction of SCCOHT-1 cells. Thus,
the effects of epothilone B which reduced the SCCOHT-1
cell growth by 20.3% ± 3.6% (n = 10) after 24 h was further
enhanced to 35.0% ± 5.3% (n = 10) together with Ca2+.
Similar synergistic effects of Ca2+ together with an epothi-
lone B-conferred growth inhibition of SCCOHT-1 cells
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(Figure 5B).
Based upon these results, further NOD/scid mouse tu-
mors were examined for a successful therapeutic ap-
proach by a daily injection of epothilone B at the tumor
site. Testing various concentrations revealed detectable
effects with 10 μM epothilone B already after 48 h (=2
treatments) with a tumor size of 2.1 ± 0.2 cm3 as com-
pared to 2.5 ± 0.1 cm3 in NaCl-treated control tumors
and a relation of tumor weight to mouse weight of
8.2 ± 0.1 in the epothilone B-treated tumor mice as com-
pared to 11.8 ± 0.6 in the NaCl-treated control tumors
(Figure 6A). Although in this first therapeutic approach,
the mice had to be sacrificed after 2 days for ethical rea-
sons due to the tumor size, these data demonstrated
already a reduction in tumor size by about 16% and a re-
duction in the relation of tumor weight to mouse weight
by about 30% after solely epothilone B treatment.
Since addition of exogenous Ca2+ supported the growth-
inhibitory effects of epothilone B in vitro, a further thera-
peutic approach was tested in vivo whereby 200 μl of
5 mM CaCl2 were injected at the tumor site and com-
pared to the effects of a co-injection of 5 mM CaCl2 +
10 μM epothilone B. Although Ca2+ alone demonstrated
little if any effects on the in vivo tumor growth, the com-
bined treatment of Ca2+ + epothilone B was associated
with a significant reduction by about 90% in the relation
of tumor weight to mouse weight after tumor dissection
of the sacrificed mice (Figure 6B). Thus, a therapeutic ap-
proach with CaCl2 + epothilone B reached a relation of
tumor weight to mouse weight of 0.5 ± 0.2 (n = 3) after 4d,
however, Ca2+ alone and the NaCl control injection
reached a relation of tumor weight to mouse weight of
5.5 ± 1.0 (n = 4) and 5.6 ± 1.7 (n = 4), respectively. Statis-
tical analysis by 1-way ANOVA revealed a significant
tumor reduction (p = 0.027) (Figure 6B). Daily consecutive
measurements and corresponding calculations of the
tumor size normalized to the size at the beginning of the
therapy (day 0) confirmed a more than 90% reduced
tumor size in CaCl2 + epothilone B-treated mice. A con-
secutive NaCl control treatment and solely Ca2+ treatment
revealed a rapidly growing and continuously increasing
tumor size to 1827% ± 656% (n = 5) and 1472% ± 196%
(n = 5) after 4d (Figure 6C). In contrast, consecutive treat-
ment with CaCl2 + epothilone B for 4d was associated
with an attenuation of tumor growth reaching an average
tumor size of 165% ± 186% (n = 4). These findings sug-
gested that a significantly reduced tumor growth of the
SCCOHT in vivo by epothilone B treatment could be
further enhanced by the addition of exogenous Ca2+
to the epothilone B therapy. This therapeutic effect of
Ca2+/epothilone B was also accompanied by an abolished
hypercalcemia in the mice. Whereas NaCl-treated control
tumor-carrying mice and Ca2+-treated mice exhibiteda hypercalcemia with average calcium levels in the blood
serum of 3.11 ± 0.75 mmol/L (n = 3) and 3.20 ± 0.40 mmol/L
(n = 4), respectively, the combined treatment of Ca2+/epothi-
lone B demonstrated normal calcium serum levels of 2.16 ±
0.53 mmol/L (n = 3).
Discussion
SCCOHT represents an aggressive female tumor with
poor prognosis and previous work has suggested a multi-
modality treatment for the SCCOHT including surgery
and a subsequent chemotherapy consisting of cisplatin-
and etoposide-based or carboplatin- and taxane-based
components followed by a radiotherapy [18,19]. Despite
this multi-modality approach, however, the level of
tumor relapses remains high and only very few patients
survived for more than two years [20-23]. Thus, the data
obtained in this study demonstrated a certain resistance
of SCCOHT-1 cells to a cisplatin- or carboplatin-based
chemotherapy since both compounds were ineffective to
decrease the proliferative capacity in vitro. Resistance to
the platin chemotherapeutics has also been confirmed for
the NIH:OVCAR-3 and SK-OV-3 ovarian cancer cells.
Moreover, the continuous and unaltered cell cycle pro-
gression of SCCOHT-1 cells in the presence of both platin
compounds is further questioning the effectiveness of
these drugs in patients with SCCOHT. Our findings are
also supported by studies in BIN-67 cells, displaying a re-
sistance to platinum and other standard chemotherapeutic
agents [24]. In contrast, microtubule-stabilizing com-
pounds such as taxol and more importantly, epothilone
B demonstrated significant anti-proliferative effects in
SCCOHT-1 as well as in NIH:OVCAR-3 and SK-OV-3
cells in vitro. The growth-inhibitory effects of epothilone
B were associated with an activation of the cellular and
DNA damage response machinery including enhanced
detection of HSP27[pSer82] and p53[pSer15], respectively,
followed by increased cell death as determined via subG1
phase cell cycle accumulation in SCCOHT-1 cells. HSP27
phosphorylation can be mediated by PKD upon cellular
stress and plays an important role in cellular protection
[25]. Moreover, DNA damage response and cell cycle ar-
rest is relayed via p53 phosphorylation including accumu-
lation of p53[pSer15] [26]. Treatment of human A2780
ovarian cancer cells with taxol has been reported with
p53 phosphorylation at serin 20 [27] whereby taxol and
epothilone B may confer signals for different phosphoryl-
ation sites at p53. In addition, epothilone-mediated cyto-
toxicity is relayed via different forms of p53 [28].
These significant cytotoxic effects of epothilone B in
SCCOHT-1 cells in vitro could also be substantiated in a
therapeutic approach of NOD/scid mouse tumor xeno-
grafts in vivo leading to an attenuated tumor growth.
The differences in epothilone B concentrations used
in vitro and in vivo can be related to protective effects
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in vitro can be exposed directly to the drug whereas
in vivo, the tumor microenvironment of extracellular
matrix with embedded adjacent cell populations includ-
ing immune cells, endothelial cells, cancer-associated fi-
broblasts and mesenchymal stem cells contribute to a
border which requires higher chemotherapeutic concen-
trations to target the tumor cells [12,13].
In this context, it is remarkable to note that the closely
related compound ixabepilone, which differs in only one
atom by the exchange of oxygen against nitrogen within
the ester bridge of the molecule, displayed no detectable
effects on SCCOHT-1 cell growth and viability even at
a 250-fold higher concentration as compared to epothi-
lone B. These significantly different cellular effects of
structurally very similar compounds are related to mo-
lecular differences in the interactions with tubulins and
the associated stability of the microtubules. Whereas
tubulinα and tubulinβ proteins associate to a heterodi-
mer and form a taxane binding pocket at intradimer
interfaces, epothilone B binding to this taxane site ex-
hibits a tight interaction with the heterodimeric tubulin
molecule and a rather static conformation. In contrast,
ixabepilone retains a significant degree of flexibility
within the atomic and molecular environment of this
taxane binding pocket and therefore displays different ef-
fects on the interaction and stability with the tubulin het-
erodimeric molecule [29]. Such molecular interactions
may also apply to the isotype form tubulinβ3 which is
present predominantly in aggressive and drug-resistant tu-
mors [30,31]. Indeed, a markedly detectable expression of
tubulinβ3 has been identified in SCCOHT-1 cells in con-
trast to the NIH:OVCAR-3 and SK-OV-3 ovarian cancer
cells which substantiates the aggressiveness of SCCOHT.
The significant epothilone B-mediated growth reduction
of SCCOHT-1 cells in vitro was maintained in re-cultured
cells from induced mouse xenograft tumors and these
findings could also be confirmed in vivo demonstrating a
tumor reduction by epothilone B in SCCOHT-1-induced
mouse xenografts. Moreover, the tumor-reducing effects
of epothilone B could be synergistically enhanced by ex-
ogenous calcium in vitro and in vivo and resulted in an at-
tenuated tumor growth. The concomitant reduction of
the hypercalcemic serum levels back to normal calcium
serum levels observed in calcium+ epothilone B-treated
mice in contrast to the sustained hypercalcemia in un-
treated and solely calcium-treated tumors appear some-
what paradoxical and suggests an important but so far
unexplained physiological role of calcium in this tumor
entity. Since increased calcium levels can exhibit cytotoxic
effects in ovarian cancer cells in vitro [32], hypercalcemia
may partially represent a defense mechanism of the organ-
ism to antagonize the rapid and aggressive tumor growth
and exogenously added calcium may further raise theselevels for a sufficient synergy with epothilone B. However,
the underlying mechanisms of this synergism remain un-
answered and require further investigation.
Conclusion
Whereas only little therapeutic strategies for unrespon-
sive ovarian carcinoma are available, the present findings
provide a more detailed understanding of potential com-
pounds to target ovarian cancer cells exhibiting resist-
ance to a variety of chemotherapeutics. Moreover, this
work demonstrates a promising disease-focused ap-
proach including some molecular explanation for target-
ing the small cell carcinoma of the ovary hypercalcaemic
type which may be embedded into a multi-modality
therapeutic approach for a better targeted treatment of
this rare cancerous disease.
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